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Abstract
Background: Quality of life is recognized as an important additional outcome measure in clinical
trials and health economic evaluations. The EQ-5D is an important generic health outcome
instrument often used for economic evaluations as a complement with disease-specific outcome
measures. In this study quality of life data was assessed using the EQ-5D-Y (new EQ-5D version
for children and adolescents) and the Cystic Fibrosis Questionnaire (CFQ). The objective of the
study is to evaluate the cross-sectional validity of the EQ-5D-Y as a generic health outcome
instrument in children and adolescents with cystic fibrosis in Germany.
Methods: In 2006 a multi-centre study was conducted in four cystic fibrosis centres in Germany.
Quality of life data from 96 patients between eight and seventeen years was collected using the EQ-
5D-Y as a generic outcome instrument and the Cystic Fibrosis Questionnaire (CFQ) as a disease-
specific instrument. Results of both instruments were compared by statistical analyses using
Spearman's rank correlations.
Results: 44.6% of the patients stated that they had no problems in any of the EQ-5D-Y dimensions.
Several low to high correlations between separate dimensions and the visual analogue scale of the
EQ-5D-Y and the different scales of the CFQ for children, their parents and adolescents can be
presented in this paper. Looking at the five EQ-5D-Y dimensions the highest correlation (rS = 0.625,
p = 0.01) was found between the dimension 'mobility' and the CFQ scale 'physical functioning' in
adolescent patients. The overall highest correlation was found between the 'subjective health
perception' and the visual analogue scale (rS = 0.744, p = 0.01) in adolescent patients older than 13
years.
Conclusion: The EQ-5D-Y can be considered a cross-sectional valid generic health outcome
instrument which reflects differences in health according to the progression of the life-long chronic
disease cystic fibrosis.
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Background
Quality of life is recognized as an important additional
outcome measure in clinical trials and health economic
evaluations. In the past two decades many instruments for
the assessment of quality of life have been developed.
Most of the developed instruments for the assessment of
quality of life are for adults. However, quality of life
instruments for children, which are applicable in healthy
as well as chronically ill children, are important and their
use in clinical research should be expanded [1].
The EQ-5D is an important generic health outcome
instrument often used for economic evaluations as a com-
plement with disease-specific outcome measures. As of
now, the EQ-5D is only validated for adults. Therefore the
internationally applicable child friendly version EQ-5D-Y
has been established by the EuroQol group and translated
into many different languages (Wille N, the EuroQol
Youth Task Force & Ravens-Sieberer U: Development of a
child-friendly EQ-5D: the EQ-5D-Y international version,
submitted). In this multi centre study quality of life data
from cystic fibrosis children and adolescents was assessed
using the EQ-5D-Y as a generic health outcome instru-
ment and the Cystic Fibrosis Questionnaire (CFQ) as a
disease-specific instrument in cystic fibrosis patients.
Cystic fibrosis is a complex lifelong chronic disease caused
by genetic mutations. In most cases multiple organ sys-
tems are affected, most patients especially suffer from
pancreatic insufficiency and lung function problems.
Hence, this chronic condition leads to irreversible organ
damages with patients having a life expectancy of only 29
years in 2007 [2].
In this article the results of the EQ-5D-Y as well as the
results of the CFQ will be analysed and correlations
between dimensions and scales of the instruments will be
demonstrated. The aim is to assess the cross-sectional
validity of the EQ-5D-Y.
Methods
The multi-centre study was based on single cross-sectional
data collection from children and adolescents between 8
to 17 years with cystic fibrosis in continuous ambulatory
treatment in four German cystic fibrosis centres (Hanno-
ver Medical School, Johann Wolfgang Goethe University
Hospital, Children's Hospital, University of Heidelberg,
and the Dr. von Haunersches Kinderspital, Ludwig Maxi-
milian University Munich) between April and August
2006. The study has been approved by the ethic commit-
tees of the involved clinics. The patients gave their consent
for the study.
Two instruments were used to collect quality of life data:
the EQ-5D-Y as a generic health outcome instrument and
the CFQ as a disease-specific instrument.
The EQ-5D consists of five dimensions of health: mobil-
ity, self-care, usual activities, pain/discomfort and anxiety/
depression. The respondent can choose the levels no (1),
some (2) or extreme (3) problems. The result is a health
profile, e.g. a patient with the health profile 11223 has no
problems with mobility and self-care, some problems
with everyday activities and pain/discomfort and extreme
problems with happiness/worry/sadness, respectively.
The visual analogue scale (VAS) included in the EQ-5D is
used to capture the patients subjective health perception
between worst imaginable health state (score 0) and best
imaginable health state (score 100) [3]. The EQ-5D was
initially constructed and validated for adult patients. The
EuroQol group now created a version for children in dif-
ferent languages. The EQ-5D-Y differs from the adult ver-
sion in changes of words which especially were adapted
for children. The German child-friendly version of the EQ-
5D (EQ-5D-Y) is available at the EuroQol group http://
www.euroqol.org. First studies about the child-friendly
EQ-5D were presented on the 23rd Scientific Plenary Meet-
ing of the EuroQol Group in Barcelona, Spain, September
14–16, 2006 [4-10].
The Cystic Fibrosis Questionnaire (CFQ) is a disease-spe-
cific instrument for quality of life measurement in cystic
fibrosis patients developed in France. Translations and
validations for German language are available [11]. The
CFQ has been developed in different versions for children
from 8 to 13 years (CFQ-k) and their parents (CFQ-e) as
well as a version for adolescents and adults aged 14 years
or older (CFQ 14+). The CFQ consists of 35 (CFQ-k), 44
(CFQ-e) or 50 (CFQ 14+) items containing different mod-
ules (quality of life, general health perception, symp-
toms), dimensions and scales, respectively. Scales in the
generic dimensions of quality of life are physical function-
ing, energy, emotional state, social limitations, everyday
life/school problems, in the disease specific dimensions
body image, eating disturbance and treatment burden.
Scales for the symptoms are weight problems, respiratory
and digestive symptoms. Answers of the patients are trans-
formed into scales between 0 (worst) and 100 (best).
According to similar concepts and content of the ques-
tionnaires high correlations (rS > 0.5, p < 0.01) are espe-
cially hypothesized for example between the EQ-5D-Y
dimension 'mobility' and the CFQ dimension 'physical
functioning', between the EQ-5D-Y dimension 'happi-
ness/worry/sadness' and the CFQ dimension 'emotional
state' as well as between the EQ-5D-Y VAS and the CFQ
dimension 'subjective health perception'. Moderate (0.3 ≤
rS ≤ 0,5) or mild correlations (rS < 0.3) are hypothesizedBMC Pediatrics 2009, 9:55 http://www.biomedcentral.com/1471-2431/9/55
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for example between the EQ-5D-Y dimension 'pain/dis-
comfort' and the and the CFQ scales 'respiratory symp-
toms' and 'digestive symptoms' as well as the EQ-5D-Y
VAS and the CFQ scales 'physical functioning' and 'emo-
tional state' could be expected for. According to different
issues no significant correlations are for example hypoth-
esized between the EQ-5D-Y dimension 'self care' and
especially for the CFQ scales 'body image'.
A subgroup analysis was made for patients with no prob-
lems on EQ-5D-Y (health profile 11111).
Statistical analyses in this paper were performed using
SPSS and EXCEL.
Results
Socio-demographic and clinical data
Data from 96 patients with an age between 8 and 17 years
were collected. 55 patients (57.3%) were between 8 and
13 years (mean age: 10.8 years) and 41 patients (42.7%)
were between 14 and 18 years old (mean age: 15.9 years).
Patients in this multi-centre study were treated in the
ambulatory cystic fibrosis centres of the Hanover Medical
School (22 patients), Johann Wolfgang Goethe University
Hospital (24 patients), Children's Hospital, University of
Heidelberg (5 patients), and the Dr. von Haunersches
Kinderspital, Ludwig Maximilian University Munich (45
patients). Clinical data is shown in table 1.
Lung function of these patients is worse than normal lev-
els especially for MEF25. In addition, the clinical data
shows, that 63.6% of all children and 73.2% of the ado-
lescents have a bacterial colonization of their lungs. About
80% of the patients have a pancreatic insufficiency. As
expected adolescents (with a longer disease history than
children) have a worse health status than those of lower
age. A significant difference between age groups can be
found especially in patients having a bacterial coloniza-
tion of the lungs (Mann-Whitney-U-Test, p = 0.011).
EQ-5D-Y dimensions and visual analogue scale (VAS)
Figure 1 presents the distribution within the EQ-5D-Y
dimensions. Between 84% and 89% of the patients
reported no problems (score 1) with 'mobility', 'self-care'
and 'usual activities'. 62% to 65% of the patients experi-
enced no problems with 'pain/discomfort' or 'happiness/
Table 1: Clinical data
Variable Children
(8 to 13 years)
(n = 55)
Adolescents
(14 to 17 years)
(n = 41)
Significance level
Sex (male) 43.6% (n = 24) 58.5% (n = 24)
Age (mean/SD) 10.8/1.7 15.9/1.80
% vital capacity (mean/SD) 92.5%/11.9% (n = 47) 97.2%/13.1% (n = 34) p = 0.082
% FEV1 (mean/SD) 93.6%/15.2% (n = 47) 90.7%/20.3% (n = 34) p = 0.618
% MEF25 (mean/SD) 68.4%/41.7% (n = 47) 58.9%/37.5% (n = 34) p = 0.273
Bacterial colonization of the lung 63.6% (n = 35) 73.2% (n = 30) p = 0.009
Pneumothorax 1.8% (n = 1) 0% (n = 0) p = 0.392
Allergic bronchopulmonary aspergillosis (ABPA) 3.6% (n = 2) 12.2% (n = 5) p = 0.229
Pancreatic insufficiency 80.0% (n = 44) 78.1% (n = 32) p = 0.782
Hepatobiliary complications 23.6% (n = 13) 26.8% (n = 11) p = 0.840
Distal intestinal obstruction 7.3% (n = 4) 0.0% (n = 0) p = 0.082
Diabetes mellitus 0.0% (n = 0) 7.3% (n = 3) p = 0.041
Nasal polyp 10.9% (n = 6) 17.1% (n = 7) p = 0.366
Isolation obligation for patient 1.8% (n = 1) 9.8% (n = 4) p = 0.081BMC Pediatrics 2009, 9:55 http://www.biomedcentral.com/1471-2431/9/55
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worry/sadness'. Only one or two patients reported
extreme problems (score 3) on at least one EQ-5D-Y
dimension.
92 patients had no missing data. Health states were
reported from health state 11111 (no problems in all
dimensions, n = 41, 44.6%) to health state 22233 (some
problems with 'mobility', 'self-care' and 'usual activities'
and extreme problems with 'pain/discomfort', n = 1,
1.1%). The high proportion of patients with no problems
hints at a ceiling effect typical for a generic instrument like
the EQ-5D-Y. However, additional analyses showed sig-
nificant differences in all but one CFQ subscale ('digestive
symptoms, Mann-Whitney-U-Test, p = 0.08) for patients
with any problem in comparison to patients without any
problems with respect to the EQ-5D-Y. Furthermore, an
subgroup analysis for patients who reported no problems
on the EQ-5D-Y resulted in no significant differences in
all CFQ subscales for patients with different clinical status,
for example in pancreatic insufficiency or bacterial coloni-
zation of the lungs see table 2.
As a result the EQ-5D-Y showed to be able to discriminate
problems in different areas.
90 patients filled out the visual analogue scale about their
subjective health perception. The mean VAS for eight to
13-year old patients was 85.4 (SD 16.4), the mean VAS for
14 to 17 year old patients was 79.4 (SD 13.2). Hence, the
VAS value is significantly better for younger patients than
for older patients (Mann-Whitney-U-Test, p = 0.006).
Correlations between EQ-5D-Y and CFQ
93 patients completed the disease-specific CFQ. 55
patients between 8 and 13 years as well as their parents
reported quality of life by the CFQ-k (for children) and
the CFQ-e (for parents). 38 adolescent patients reported
their quality of life by the CFQ 14+ (for patients older
than 14 years).
Correlations between EQ-5D-Y dimensions and the CFQ
scales are reported in table 3. If the correlation (Spear-
man's rank correlation) is significant at a significance level
of 0.01 it is marked with two stars (**). One star (*) indi-
cates that the correlation is significant at a level of 0.05
(non-significant correlations are reported as n.s.).
For all CFQ versions the EQ-5D-Y dimension 'mobility'
correlates moderately (0.3 ≤ rS ≤ 0.5, p < 0.01) or highly
(rS > 0.5, p < 0.01) with the scale 'physical functioning'.
For the dimension 'self care' several mild (rS < 0.3, p <
Distribution of EQ-5D-Y dimensions (n = 94) Figure 1
Distribution of EQ-5D-Y dimensions (n = 94).BMC Pediatrics 2009, 9:55 http://www.biomedcentral.com/1471-2431/9/55
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0.01) or moderate (0.3 ≤ rS ≤ 0.5, p < 0.01) correlations
with CFQ scales can be found, but overall the correlations
of this dimension are the lowest in comparison to the
other dimensions. The dimension 'everyday activities'
shows several moderate correlations especially with the
scales 'physical functioning', 'emotional state', 'everyday
life' and 'treatment burden'. Some CFQ scales correlate
highly to the EQ-5D-Y dimension 'pain/discomfort'. For the
dimension 'happiness/worry/sadness' the highest correlation
(rS = 0.586, p = 0.01) can be found with the CFQ scale
'emotional state' in adolescent patients.
For all CFQ versions the visual analogue scale shows mod-
erate or high correlations (rS > 0.3, p < 0.01) with the CFQ
scales 'physical functioning', 'energy', 'school problems'
and 'everyday life', 'subjective health perception', and 'res-
piratory symptoms'. The overall highest correlation (rS =
0.744, p = 0.01) can be found between 'subjective health
perception' and the visual analogue scale in adolescent
patients.
Only a few statistically significant correlations between
clinical data and quality of life data can be found. The
dimension 'usual activities' shows low correlations with
the '% of vital capacity' (rS = 0.248, p < 0.05) and if a
patient has to be isolated according to a bacterial coloni-
zation of his lungs (rS = 0.281, p < 0.01). The visual ana-
logue scale correlates moderately especially with age (rS =
0.339, p < 0.01) and weakly with a bacterial colonization
of the lungs (rS = 0.215, p < 0.05). Therefore differences in
clinical data seem not to have a major impact on quality
of life data.
Discussion
Summary of the results
44.6% of the patients stated that they had no problems in
any of the EQ-5D-Y dimensions. The high proportion of
patients with no problems hints at a ceiling effect typical
for a generic instrument like the EQ-5D-Y. However, addi-
tional analyses showed that the EQ-5D-Y is able to dis-
criminate problems in different areas.
Several low to strong correlations between the dimensions
of the EQ-5D-Y and the scales of the CFQ for children,
their parents and adolescents could be found in the anal-
ysis. Looking at the five EQ-5D-Y dimensions the highest
correlation (rS = 0.625, p = 0.01) was found between the
dimension 'mobility' and the CFQ scale 'physical func-
tioning' in adolescent patients. For all CFQ versions the
visual analogue scale showed moderate or high correlations
(rS > 0.3) with several CFQ scales. The overall highest cor-
relation was found between the 'subjective health percep-
tion' and the visual analogue scale (rS = 0.744, p = 0.01)
in adolescents. Hence, the hypothesized associations were
confirmed.
Only a few correlations between clinical data and quality
of life data were found. Therefore, differences in clinical
data may not have a major impact on quality of life data
for cystic fibrosis children and adolescents.
Interpretation of the results
It is noticeable that in many cases patients reported about
a good EQ-5D health state despite their strong disease
according to the medical classification of disease activity.
The objective health state may be actually lower (worse)
Table 2: Subgroup analysis for patients without problems on EQ-5D-Y
Pancreatic insufficiency (PI) Bacterial colonization (BC)
Mean without PI (SD)/Mean with PI (SD) Significance level Mean without BC (SD)/Mean with BC 
(SD)
Significance level
Physical functioning 91.7 (14.0)/92.2 (12.4) p = 0.985 95.9 (4.7)/89.4 (15.2) p = 0.337
Emotional state 85.5 (10.9)/87.5 (10.4) p = 0.616 88.1 (11.5)/86.1 (9.7) p = 0.408
Social limitations 66.4 (14.4)/72.6 (11.2) p = 0.143 73.1 (12.3)/69.7 (11.3) p = 0.469
Body image 79.4 (17.5)/87.5 (20.0) p = 0.153 85.2 (24.7)/87.5 (16.2) p = 0.987
Eating disturbance 88.9 (17.0)/94.8 (9.8) p = 0.344 91.9 (12.9)/94.7 (10.6) p = 0.376
Treatment burden 77.8 (17.0)/74.0 (19.3) p = 0.765 68.1 (20.1)/77.8 (16.8) p = 0.135
Respiratory symptoms 82.1 (11.7)/86.0 (16.2) p = 0.212 88.0 (9.3)/83.1 (18.2) p = 0.509
Digestive symptoms 76.2 (16.3)/78.5 (20.1) p = 0.613 75.6 (19.3)/80.2 (19.8) p = 0.457BMC Pediatrics 2009, 9:55 http://www.biomedcentral.com/1471-2431/9/55
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Table 3: Correlations between EQ-5D-Y dimensions and CFQ scales
Mobility Self care Everyday activities Pain/discomfort Happiness/worry/sadness VAS
Physical functioning CFQk -0.459 (**) -0.309 (*) -0.379 (**) -0.419 (**) -0.299 (*) 0.401 (**)
CFQe -0.516 (**) -0.307 (*) -0.438 (**) -0.417 (**) -0.267 (n.s.) 0.495 (**)
CFQ 14+ -0.625 (**) -0.495 (**) -0.472 (**) -0.247 (n.s.) -0.149 (n.s.) 0.576 (**)
Energy CFQe -0.248 (n.s.) -0.181 (n.s.) -0.263 (n.s.) -0.509 (**) -0.315 (*) 0.469 (**)
CFQ 14+ -0.248 (n.s.) -0.358 (**) -0.266 (n.s.) -0.408 (**) -0.396 (**) 0.726 (**)
Emotional state CFQk -0.188 (n.s.) -0.096 (n.s.) -0.286 (*) -0.507 (**) -0.345 (*) 0.308 (*)
CFQe -0.428 (**) -0.317 (*) -0.402 (**) -0.517 (**) -0.421 (**) 0.445 (**)
CFQ 14+ -0.337 (**) -0.451 (**) -0.373 (**) -0.433 (**) -0.586 (**) 0.567 (**)
Social limitations CFQk -0.338 (*) -0.201 (n.s.) -0.255 (n.s.) -0.350 (**) -0.314 (*) 0.277 (n.s.)
CFQ 14+ -0.255 (n.s.) -0.200 (n.s.) -0.309 (n.s.) -0.315 (n.s.) 0.030 (n.s.) 0.435 (**)
School problems CFQe -0.316 (*) -0.268 (n.s.) -0.327 (*) -0.519 (**) -0.362 (**) 0.452 (**)
Everyday life CFQ 14+ -0.410 (**) -0.365 (**) -0.461 (**) -0.599 (**) -0.412 (**) 0.553(**)
Body image CFQk -0.171 (n.s.) -0.178 (n.s.) -0.292 (*) -0.293 (*) -0.391 (**) 0.347 (*)
CFQe -0.180 (n.s.) -0.234 (n.s.) -0.234 (n.s). -0.279 (*) -0.265 (n.s.) 0.327 (*)
CFQ 14+ -0.139 (n.s.) -0.427 (*) -0.459 (**) -0.425 (**) -0.235 (n.s.) 0.551 (**)
Eating disturbance CFQk -0.294 (*) -0.338 (*) -0.343 (*) -0.311 (*) -0.186 (n.s.) 0.187 (n.s.)
CFQe -0.286 (*) -0.253 (n.s.) -0.175 (n.s.) -0.139 (n.s.) 0.032 (n.s.) 0.170 (n.s.)
CFQ 14+ -0.367 (**) -0.465 (**) -0.391 (**) -0.174 (n.s.) -0.256 (n.s.) 0.315 (n.s.)
Treatment burden CFQk -0.155 (n.s.) -0.168 (n.s.) -0.433 (**) -0.365 (**) -0.340 (*) 0.166 (n.s.)
CFQe -0.229 (n.s.) -0.168 (n.s.) -0.361 (**) -0.254 (n.s.) -0.346 (*) 0.315 (n.s.)
CFQ 14+ -0.298 (n.s.) -0.473 (**) -0.282 (n.s.) -0.217 (n.s.) -0.320 (n.s.) 0.439 (**)
Subjective health 
perception
CFQe -0.336 (*) -0.308 (*) -0.380 (**) -0.508 (**) -0.364 (**) 0.379 (**)
CFQ 14+ -0.435 (**) -0.357 (**) -0.349 (**) -0.470 (**) -0.460 (**) 0.744 (**)
Weight problems CFQe -0.116 (n.s.) -0.347 (*) -0.123 (n.s.) -0.355 (**) -0.129 (n.s.) 0.266 (n.s).
CFQ 14+ -0.374 (**) -0.495 (*) -0.533 (**) -0.240 (n.s.) -0.233 (n.s.) 0.256 (n.s.)
Respiratory symptoms CFQk -0.235 (n.s.) 0.004 (n.s.) -0.328 (*) -0.315 (*) -0.304 (*) 0.393 (**)
CFQe -0.434 (**) -0.228 (n.s.) -0.383 (**) -0.376 (**) -0.302 (*) 0.450 (**)
CFQ 14+ -0.469 (**) -0.258 (n.s.) -0.286 (n.s.) -0,259 (n.s.) -0.457 (**) 0.592 (**)BMC Pediatrics 2009, 9:55 http://www.biomedcentral.com/1471-2431/9/55
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than reported. An explanation might be coping, which
means that patients learn to live with the disease and do
not perceive limitations as bad as expected.
Different significance levels for correlations between EQ-
5D-Y dimensions and CFQ scales might result from the
fact, that some dimensions of the EQ-5D-Y and scales of
the CFQ are directed at exactly the same issue (for exam-
ple the visual analogue scale of the EQ-5D-Y and the CFQ
scale 'subjective health perception') and others only par-
tially. Furthermore a reason for higher correlations of the
visual analogue scale in comparison to the EQ-5D-Y
dimensions might be the continuous character of the scale
instead of the three score levels.
Although the time frame of the EQ-5D-Y (today) is differ-
ent to the time frame of the CFQ (last two weeks), signif-
icant correlation results were found. However, it is
possible that correlations within the same time frame still
would be higher than those reported.
For further research it would be interesting to compare
different properties of the used measures in a setting with
multiple and continuous assessments at various time
points.
Conclusion
Data was collected in a multi centre study from a repre-
sentative patient group of children and adolescents with
cystic fibrosis. The analysis showed several correlations
between the different dimensions and the visual analogue
scale of the EQ-5D-Y and the scales of the different CFQ
versions for children, their parents and adolescents.
Therefore, the EQ-5D-Y can be considered a cross-sec-
tional valid generic health outcome measure which
reflects differences in health according to the progression
of the life long chronic disease cystic fibrosis.
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